Anti-ulcer composition
AssigneeThe Proctor & Gamble Company
InventorRobert G. Laughlin
Life of this patent
Estimating the term…
Abstract
Zwitterionic surfactant compounds provide effective therapy for ulceration of the gastric mucosa. The tendency of aspirin and other salicylate-based drugs to cause ulceration of the gastric mucosa is also reduced by administration of such drugs in conjunction with certain zwitterionic surfactants. The ammoniohexanoate zwitterionics are especially preferred in the management of both gastric and duodenal ulcers.
Claims16
A composition of matter for oral administration comprising:
- (a) a safe and effective amount of a conventional antacid;
- and
- (b) a zwitterionic compound selected from the group consisting of
- n-C.sub.12 H.sub.25 N.sup.+ (CH.sub.3).sub.2 (CH.sub.2).sub.5 CO.sub.2.sup.-,
- n-C.sub.14 H.sub.29 N.sup.+ (CH.sub.3).sub.2 -(CH.sub.2).sub.5 CO.sub.2.sup.-,
- n-C.sub.16 H.sub.33 N.sup.+ (CH.sub.3).sub.2 (CH.sub.2).sub.5 CO.sub.2.sup.-,
- n-C.sub.18 H.sub.37 N.sup.+ (CH.sub.3).sub.2 (CH.sub.2).sub.5 CO.sub.2.sup.-,
- n-C.sub.20 H.sub.41 N.sup.+ (CH.sub.3).sub.2 (CH.sub.2).sub.5 CO.sub.2.sup.-, and
- n-C.sub.22 H.sub.45 N.sup.+ (CH.sub.3).sub.2 (CH.sub.2).sub.5 CO.sub.2.sup.-, and esters and salts thereof in an amounts which is safe and effective for preventing or relieving ulceration of the gastric mucosa.
A composition of matter for oral administration comprising:
- (a) a safe and effective amount of a salycilate-based drug;
- and
- (b) a zwitterionic compound selected from the group consisting of n-C.sub.12 H.sub.25 N.sup..sym. (CH.sub.3).sub.2 (CH.sub.2).sub.5 CO.sub.2.sup..crclbar., n-C.sub.14 H.sub.29 N.sup..sym. -(CH.sub.3).sub.2 (CH.sub.2).sub.5 CO.sub.2.sup..crclbar., n-C.sub.16 H.sub.33 N.sup..sym. (CH.sub.3).sub.2 (CH.sub.2).sub.5 CO.sub.2.sup..sym., n-C.sub.18 H.sub.37 N.sup..sym. -(CH.sub.3).sub.2 (CH.sub.2).sub.5 CO.sub.2.sup..crclbar., n-C.sub.20 H.sub.41 N.sup..sym. (CH.sub.3).sub.2 (CH.sub.2).sub.5 CO.sub.2.sup..crclbar., and n-C.sub.22 H.sub.45 N.sup..sym. (CH.sub.3).sub.2 (CH.sub.2).sub.5 CO.sub.2.sup..crclbar., and ester salts thereof in an amount which is safe and effective for preventing or relieving ulceration of the gastric mucosa.
A process for preventing or relieving ulceration of the gastric mucosa in a human or lower animal in need of such treatment by orally administering thereto at least about 18 mg/kg of body weight per day of a zwitterionic compound selected from the group consisting of n-C.sub.12 H.sub.25 N.sup..sym. (CH.sub.3).sub.2 (CH.sub.2).sub.5 CO.sub.2.sup..crclbar., n-C.sub.14 H.sub.29 N.sup..sym. -(CH.sub.3).sub.2 (CH.sub.2).sub.5 CO.sub.2.sup..crclbar., n-C.sub.16 H.sub.33 N.sup..sym. (CH.sub.3).sub.2 (CH.sub.2).sub.5 CO.sub.2.sup..crclbar., n-C.sub.18 H.sub.37 N.sup..sym. -(CH.sub.3).sub.2 (CH.sub.2).sub.5 CO.sub.2.sup..crclbar., n-C.sub.20 H.sub.41 N.sup..sym. (CH.sub.3).sub.2 (CH.sub.2).sub.5 CO.sub.2.sup..crclbar., and n-C.sub.22 H.sub.45 N.sup..sym. (CH.sub.3).sub.2 (CH.sub.2).sub.5 CO.sub.2.sup..crclbar., and ester salts thereof.
Dependencies are inferred from the claim text.